UBS Group’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.9K | Sell |
56,004
-195,701
| -78% | -$147K | ﹤0.01% | 7614 |
|
|
2025
Q4 | $194K | Buy |
251,705
+51,469
| +26% | +$46.4K | ﹤0.01% | 6594 |
|
|
2025
Q3 | $202K | Sell |
200,236
-342,785
| -63% | -$403K | ﹤0.01% | 6662 |
|
|
2025
Q2 | $722K | Buy |
543,021
+291,865
| +116% | +$396K | ﹤0.01% | 5709 |
|
|
2025
Q1 | $299K | Buy |
251,156
+201,098
| +402% | +$286K | ﹤0.01% | 6246 |
|
|
2024
Q4 | $81.6K | Buy |
50,058
+29,824
| +147% | +$78.9K | ﹤0.01% | 6998 |
|
|
2024
Q3 | $77.3K | Sell |
20,234
-39,754
| -66% | -$133K | ﹤0.01% | 6537 |
|
|
2024
Q2 | $176K | Buy |
59,988
+17,101
| +40% | +$54.7K | ﹤0.01% | 5756 |
|
|
2024
Q1 | $170K | Buy |
42,887
+27,074
| +171% | +$139K | ﹤0.01% | 5960 |
|
|
2023
Q4 | $78.6K | Buy |
15,813
+15,338
| +3,229% | +$76.2K | ﹤0.01% | 6317 |
|
|
2023
Q3 | $2.4K | Sell |
475
-7,025
| -94% | -$38.5K | ﹤0.01% | 7711 |
|
|
2023
Q2 | $37.7K | Buy |
7,500
+4,900
| +188% | +$32.1K | ﹤0.01% | 6617 |
|
|
2023
Q1 | $16K | Buy |
+2,600
| New | +$21.3K | ﹤0.01% | 7255 |
|
|
2022
Q4 | – | Sell |
-9,883
| Closed | -$30K | – | 11031 |
|
|
2022
Q3 | $30K | Buy |
+9,883
| New | +$41.9K | ﹤0.01% | 6887 |
|
|
2022
Q2 | – | Sell |
-2,499
| Closed | -$15K | – | 10761 |
|
|
2022
Q1 | $15K | Buy |
+2,499
| New | +$15.5K | ﹤0.01% | 7837 |
|
|
2021
Q4 | – | Sell |
-2,946
| Closed | -$44K | – | 10582 |
|
|
2021
Q3 | $44K | Buy |
+2,946
| New | +$36.7K | ﹤0.01% | 6445 |
|
|
2021
Q1 | – | Sell |
-104,890
| Closed | -$224K | – | 9343 |
|
|
2020
Q4 | $224K | Buy |
104,890
+1,311
| +1% | +$2.87K | ﹤0.01% | 5170 |
|
|
2020
Q3 | $241K | Buy |
+103,579
| New | +$290K | ﹤0.01% | 4686 |
|
|
2020
Q2 | – | Sell |
-38,400
| Closed | -$28K | – | 8256 |
|
|
2020
Q1 | $28K | Buy |
38,400
+32,950
| +605% | +$57.1K | ﹤0.01% | 6273 |
|
|
2019
Q4 | $14K | Buy |
+5,450
| New | +$15.5K | ﹤0.01% | 7095 |
|
|
2019
Q3 | – | Sell |
-1,583
| Closed | -$9K | – | 8186 |
|
|
2019
Q2 | $9K | Buy |
+1,583
| New | +$10.4K | ﹤0.01% | 7136 |
|
|
2018
Q4 | – | Sell |
-1,545
| Closed | -$25K | – | 8221 |
|
|
2018
Q3 | $25K | Sell |
1,545
-635
| -29% | -$11.4K | ﹤0.01% | 6668 |
|
|
2018
Q2 | $45K | Buy |
2,180
+1,180
| +118% | +$24.6K | ﹤0.01% | 6063 |
|
|
2018
Q1 | $24K | Buy |
1,000
+955
| +2,122% | +$257K | ﹤0.01% | 6281 |
|
|
2017
Q4 | $8K | Buy |
45
+12
| +36% | +$2.42K | ﹤0.01% | 7162 |
|
|
2017
Q3 | $7K | Buy |
+33
| New | +$6.82K | ﹤0.01% | 7080 |
|
|
2017
Q2 | – | Sell |
-23
| Closed | -$4K | – | 7898 |
|
|
2017
Q1 | $4K | Sell |
23
-188
| -89% | -$37.2K | ﹤0.01% | 7080 |
|
|
2016
Q4 | $52K | Buy |
211
+125
| +145% | +$28.4K | ﹤0.01% | 5801 |
|
|
2016
Q3 | $18K | Sell |
86
-5
| -5% | -$991 | ﹤0.01% | 6385 |
|
|
2016
Q2 | $18K | Buy |
+91
| New | +$16.1K | ﹤0.01% | 6386 |
|
|
2016
Q1 | – | Sell |
-86
| Closed | -$21K | – | 8026 |
|
|
2015
Q4 | $21K | Buy |
+86
| New | +$27.7K | ﹤0.01% | 6715 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
UBS Group's PDSB Position: Q1 2026 in Review
UBS Group reduced its PDS Biotechnology (PDSB) stake by 78% in Q1 2026, selling an estimated $147K and leaving 56,004 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7614.
UBS Group first reported a position in PDSB in Q4 2015 and has held it in 31 quarters since. The position peaked at $722K in Q2 2025. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- UBS Group held 56,004 shares of PDS Biotechnology worth $33.9K as of Q1 2026.
- UBS Group sold 195,701 PDS Biotechnology shares in Q1 2026, an estimated $147K.
- PDS Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7614 holding.
- UBS Group first reported a position in PDS Biotechnology in Q4 2015 and has held it in 31 quarters since.
- UBS Group's PDS Biotechnology position peaked at $722K in Q2 2025.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.